Price of Global Health

Regular price €167.40
A01=Ed Schoonveld
Access Journey
Accountable Care Organizations
Age Group_Uncategorized
Age Group_Uncategorized
ASMR
Author_Ed Schoonveld
automatic-update
Biosimilar Market
Biosimilars Industry
biotechnology
Category1=Non-Fiction
Category=KFFM
Category=KJMV7
Category=KJS
Category=KND
Category=KNDP
Compulsory Licensing
Confidential Rebates
COP=United Kingdom
Current Treatment Alternatives
Delivery_Delivery within 10-20 working days
drug economics
drug pricing
DTC
DTC Advertising
EMA Approval
eq_business-finance-law
eq_isMigrated=2
eq_non-fiction
gGlobal drug pricing
Global Pricing Strategy
Health Technology Assessment
healthcare industry
healthcare management
HTA
International Price Referencing
Joint Federal Committee
Language_English
market access
Orphan Drugs
PA=Available
Parallel Trade
patient access
patient access issues
Patient Reported Outcomes
pharmaceutical industry
pharmaceutical pricing
PPRS.
Price Volume Agreement
Price_€100 and above
pricing strategy
PS=Active
Risk Sharing Deals
softlaunch
Therapeutic Referencing
TNF Inhibitor
Ultra-rare Diseases
vocal medical community

Product details

  • ISBN 9780367279400
  • Weight: 1423g
  • Dimensions: 174 x 246mm
  • Publication Date: 03 Jun 2020
  • Publisher: Taylor & Francis Ltd
  • Publication City/Country: GB
  • Product Form: Hardback
  • Language: English
Delivery/Collection within 10-20 working days

Our Delivery Time Frames Explained
2-4 Working Days: Available in-stock

10-20 Working Days
: On Backorder

Will Deliver When Available
: On Pre-Order or Reprinting

We ship your order once all items have arrived at our warehouse and are processed. Need those 2-4 day shipping items sooner? Just place a separate order for them!

The Price of Global Health is a unique book that describes the pharmaceutical pricing process and its business, economic and social challenges. Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can a life-saving industry have a poorer image than gun and tobacco industries, whose products are associated with death?

The pharmaceutical industry is under unprecedented pressure due to a combination of declining R&D productivity, payer/provider demands for better value and public pressures to show pricing restraint. Rapidly increasing cost of healthcare, shifts from fee-for-service to value-based reimbursement, public pressure on drug pricing and an increasingly vocal medical community have empowered public and private payers worldwide to be more demanding on evidence of value for the prescription drugs that are brought to market. Pharmaceutical companies have often failed to deliver evidence of patient value, as development decision-making is overly focused on speed to FDA approval rather than speed to commercial success by effectively addressing the many “Access Journey” obstacles that typify today’s much changed pharmaceutical environment.

This 3rd edition is significantly expanded with ten new chapters and revised and updated throughout to reflect today’s environment. The contents are reorganized to directly address critical pricing and patient access issues. Ed Schoonveld explains how pharmaceutical prices are determined in a complex global payer environment and what factors influence the process. His insights will help a wide range of audiences from healthcare industry professionals to policy makers, consumers, pharmaceutical company leaders and access and pricing professionals to gain a better understanding of this highly complex and emotionally charged field.

Ed Schoonveld has 30+ years of experience in pharmaceutical pricing and access. He is currently Managing Partner of the Value and Access Practice with ZS Associates. He led global pricing functions for Wyeth, Lilly and BMS and consulting practices in Cambridge Pharma/IMS and Analytica International.